PMID- 17091295
OWN - NLM
STAT- MEDLINE
DCOM- 20070824
LR  - 20181113
IS  - 0014-4819 (Print)
IS  - 0014-4819 (Linking)
VI  - 178
IP  - 4
DP  - 2007 Apr
TI  - IVIG enters the central nervous system during treatment of experimental 
      autoimmune encephalomyelitis and is localised to inflammatory lesions.
PG  - 462-9
AB  - Intravenous immunoglobulin (IVIG) treatment reduces the relapse rate in 
      relapsing-remitting multiple sclerosis (MS) and may interfere with MS pathology 
      through its various anti-inflammatory and immunomodulatory properties. It is 
      presently unknown whether IVIG enters the central nervous system (CNS) in 
      sufficient amounts to influence the local immune response within the brain and 
      spinal cord, or if the treatment effects are entirely due to peripheral actions 
      of IVIG. The purpose of the present study was to evaluate if IVIG radiolabeled 
      with 99mTc enters the CNS during treatment of experimental autoimmune 
      encephalomyelitis (EAE) in the susceptible rat strain Dark Agouti. After in vivo 
      administration of 99mTc-IVIG we observed significantly increased accumulation in 
      the brain and spinal cord from rats with EAE. Accumulation of 99mTc-IVIG was not 
      detectable in CNS tissue from control animals. In peripheral tissue samples minor 
      increases in 99mTc-IVIG organ binding were observed in the liver and kidney 
      during EAE. Localisation of 99mTc-IVIG in the brain tissue was visualised by 
      autoradiography and revealed significant accumulation of IVIG only in areas also 
      affected by perivascular inflammation and leakage of serum proteins. In 
      conclusion, the results indicate that significant extravasation of IVIG to the 
      CNS only occurs when blood-brain barrier function is compromised during EAE.
FAU - Jorgensen, Signe Humle
AU  - Jorgensen SH
AD  - Danish MS Research Center, Department of Neurology, Copenhagen University 
      Hospital, Rigshospitalet sect. 6311, 2100 Copenhagen, Denmar. shj@astion.com
FAU - Storm, Nicolas
AU  - Storm N
FAU - Jensen, Poul Erik Hyldgaard
AU  - Jensen PE
FAU - Laursen, Henning
AU  - Laursen H
FAU - Sorensen, Per Soelberg
AU  - Sorensen PS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061108
PL  - Germany
TA  - Exp Brain Res
JT  - Experimental brain research
JID - 0043312
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Animals
MH  - Body Weight/drug effects
MH  - Central Nervous System/*drug effects/metabolism
MH  - Disease Models, Animal
MH  - Drug Administration Routes
MH  - Encephalomyelitis, Autoimmune, Experimental/complications/*drug 
      therapy/metabolism/pathology
MH  - Immunoglobulins, Intravenous/pharmacokinetics/*therapeutic use
MH  - Immunologic Factors/pharmacokinetics/*therapeutic use
MH  - Inflammation/etiology/prevention & control
MH  - Male
MH  - Radiopharmaceuticals/pharmacokinetics
MH  - Rats
MH  - Time Factors
MH  - Tissue Distribution
EDAT- 2006/11/09 09:00
MHDA- 2007/08/25 09:00
CRDT- 2006/11/09 09:00
PHST- 2006/05/05 00:00 [received]
PHST- 2006/10/06 00:00 [accepted]
PHST- 2006/11/09 09:00 [pubmed]
PHST- 2007/08/25 09:00 [medline]
PHST- 2006/11/09 09:00 [entrez]
AID - 10.1007/s00221-006-0752-8 [doi]
PST - ppublish
SO  - Exp Brain Res. 2007 Apr;178(4):462-9. doi: 10.1007/s00221-006-0752-8. Epub 2006 
      Nov 8.